Pharmacokinetics, toxicity, side effects, receptor affinities and in vitro radiosensitizing effects of the novel metoclopramide formulations, sensamide and neu-sensamide

Pharmacology and Toxicology

Volumn 80, Issue 5, 1997, Pages 231-239

  Pero, Ronald W ^a   Olsson, Anders ^a   Simanaitis, Mecislovas ^b   Amiri, Amir ^a   Andersen, Inger ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; DOPAMINE 2 RECEPTOR; METOCLOPRAMIDE; SEROTONIN 3 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CHO CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG RECEPTOR BINDING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE ATROPHY; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; RAT; SEDATION;

ANIMALIA;

EID: 0030986377     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1997.tb01965.x     Document Type: Article

References (29)

1. Bakke, O. M. & J. Segura : The absorption and elimination of meto-clopramide in three animal species. J. Pharm. Pharmacol. 1976, 28, 32-39.
2. Bateman, D. N., C. Kahn, D. S. Davies: The pharmacokinetics of metoclopramide in man with observations in the dog. Brit. J. Clin. Pharmacol. 1980, 9, 371-377.
3. Bateman, D. N., S. J. Proctor, M. D. Rawlins, W. B. Taylor: Kinetics and efficacy of high-dose metoclopramide used in the prevention of cytotoxic-induced nausea and vomiting. Brit. J. Pharmacol 1983, 79, 490P.
4. Brechot, J.M., J. P. Dupeyron, C. Delattre, Cl. Chastang, J. P. Laaban, J. Rochemaure: Continuous infusion of high-dose metoclopramide: comparison of pharmacokinetically adjusted and standard doses for the control of cisplatin-induced acute emesis. Eur. J. Clin. Pharmacol. 1991, 40, 283-286.
5. Citron, M. L., J. R. Reynolds, J. Kalra, B. G. Kay, K. A. Nathan, N. D. Jaffe & F. R. Miller: Pharmacokinetic comparison of intranasal, oral, and intramuscular metoclopramide in healthy volunteers. Cancer Treatm. Rep. 1987, 71, 317-319.
6. D'Amico, A.V. & W. G. McKenna: Apoptosis and a re-investigation of the biologic basis for cancer therapy. Radiotherap. Oncol. 1994, 33, 3-10.
7. FASS 1996 xxx
8. Graffner, C., P. O. Lagerström, P. Lundborg & O. Rönn: Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography. Brit. J. Clin. Pharmacol. 1979, 8, 469-474.
9. Hayes, G., T. J. Biden, L. A. Selbie & J. Shine: Structural subtypes of the dopamine D2 receptor are functionally distinct: Expression of the cloned D2A and D2B subtypes in a heterologous cell line. Mol. Endocrin. 1992, 6, 920-925.
10. Harrington, R. A., C. W. Hamilton, R. N. Brogden, J. A. Linkewich, J. A. Romankiewicz & R. C. Heel: Metoclopramide, an updated review of its pharmacological properties and clinical use. Drugs 1983, 25, 451-494.
11. Hanoco, M., J. Topart, xx van Damme & L. Molle: Détermination des constantes d'ionisation de quelques N-(die'thylamino-2-ethyl) bensamides substitués. J. Pharm. Belg. 1973, 28, 649-662.
12. Hua J., A. Olsson, Y. Sheng & R. W. Pero: Acidic and neutralized metoclopramide formulations sensitize ionizing radiation induced cytotoxicity in a human lung adenocarcinoma xenografted to seid mice. Anti-Cancer Drugs 1995, 6, 451-455.
13. Kerr, F. R. & C. M. Winterford: Apoptosis. Its significance in cancer and cancer therapy. Cancer 1993, 73, 2013-2026.
14. 3 receptor antagonists. Drugs of the Future 1989, 14, 875-889.
15. Kjellén, E., J. Wennerberg & R. W. Pero: Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck. Brit. J. Cancer 1989, 59, 247-250.
16. Kjellén, E., R. W. Pero, E. Brun, S.-B. Ewers, O. Jarlman, T. Knöös, P. Malmström, J. Tennvall, D. Killander, A. Olsson, Y. Sheng & J. Wennerberg: A Phase I/II evaluation of metoclopramide as a radiosensitizer in patients with inoperable squamous cell carcinoma of the lung. Eur. J. Cancer 1995, 31A(13/14), 2196-2202.
17. Lybak, S., E. Kjellén, J. Wennerberg & R. W. Pero: Metoclopramide enhances the effect of ionizing radiation on xenografted squamous cell carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 1990, 19, 1419-1424.
18. Lybak, S. & R. W Pero: The benzamide derivative metoclopramide causes DNA damage and inhibition of DNA repair in human peripheral mononuclear leukocytes at clinically relevant doses. Carcinogenesis. 1991, 12, 1613-1617.
19. Lybak, S., E. Kjellén, P. Nilsson, A. Tomaszewicz, J. Wennerberg & R. W. Pero: Normal tissue reactions in mice after combined treatment with metoclopramide and ionizing radiation. Acta oncol. 1992, 31, 469-474.
20. Meyer, B. R., M. Lewin, D. E. Drayer, M. Pasmantier, L. Lonski & M. M. Reidenberg: Optimizing metoclopramide control of cisplatin induced emesis. Ann. Int. Med. 1984, 100, 393-395.
21. Olsson, A., Y. Sheng, E. Kjellén & R. W. Pero: In vivo tumor measurement of DNA damage, DNA repair and NAD pools as indicators of radiosensitization by metoclopramide. Carcinogenesis 1995, 16, 1029-1035.
22. Pero, R.W., A. Olsson, Y. Sheng, J. Hua, C. Möller, E. Kjellén, D. Killander & M. Marmor: Progress in identifying clinical relevance of inhibition, stimulation and measurements of poly ADP-ribosylation. Biochimie 1995, 77, 385-393.
23. 3 binding sites. Eur. J. Pharmacol. 1989, 168, 355-362.
24. Rotmensch, H. H., L. D. Mau, J. A. Satton, S. Kilminster, C. Möller & R. W. Pero: Comparative central neurons system effects and pharmacokinetics of Neu-Sensamide and Metoclopramide in healthy volunteers. J. Clin. Pharmacol. 1997, in press.
25. Salford, L. G., R. W. Pero, A. T. Aas & A. Brun: Metoclopramide as a sensitizer of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) treatment of brain tumors in the rat. Anti-Cancer Drugs 1992, 3, 267-272.
26. Tam, Y. K., J. E. Axelson, B. McErlane, R. P. Kapil, K. W. Riggs, R. Ongley & J. D. E. Price: The pharmacokinetics of metoclopramide in rats with experimental renal and hepatic dysfunction. J. Pharmacol. Exp. Therap. 1981, 219, 141-146.
27. Tyson, L. B., R. J. Gralla, M. G. Kris, C. W. Young & R. A. Clark: Dose-ranging antiemetic trial of high-dose oral metoclopramide. Amer. J. Clin. Oncol. 1989, 12, 239-243.
28. van de Waterbeemd, H., P. A. Carrupt & B. Testa: Similarities of pharmacophoric patterns revealed by the MEP of metoclopramide, molindone and piquindone, a subgroup of dopamine D-2 receptor antagonists. J. Mol. Graph. 1986, 4, 51-55.
29. Werning, J. W., D. W. Stepnick, A. Jafri, C. A. Megerian, A. R. Antunez & S. I. A. Zaidi : Metoclopramide enhances the effect of photodynamic therapy on xenografted human squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head. Neck Surg. 1995, 121, 783-789.